The paradoxical role of IL-10 in immunity and cancer

被引：504

作者：

Mannino, Mark H. ^{[1
]}

Zhu, Ziwen ^{[1
]}

Xiao, Huaping ^{[2
,3
]}

Bai, Qian ^{[1
]}

Wakefield, Mark R. ^{[1
]}

Fang, Yujiang ^{[1
,2
]}

机构：

[1] Univ Missouri, Sch Med, Dept Surg, Columbia, MO 65212 USA

[2] Des Moines Univ, Dept Microbiol Immunol & Pathol, Des Moines, IA 50312 USA

[3] Xiangnan Univ, Affilated Hosp, Chenzhou 423000, Hunan, Peoples R China

来源：

CANCER LETTERS | 2015年 / 367卷 / 02期

关键词：

IL-10; Cancer; Immune; NATURAL-KILLER-CELLS; INHIBITS CYTOKINE PRODUCTION; HUMAN-MELANOMA CELLS; EFFECTOR T-CELLS; FUNCTIONAL-CHARACTERIZATION; INTERLEUKIN-10; PRODUCTION; DENDRITIC CELLS; GROWTH-FACTOR; ACTIVATED MACROPHAGE; SIGNALING PATHWAY;

D O I：

10.1016/j.canlet.2015.07.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Interleukin-10 (IL-10) produced by a wide-variety of cells is a highly pleiotropic cytokine. It has been implicated in the pathogenesis and/or development of autoimmune diseases and cancer, although it displays differential effects that seem to be contradictory sometimes. The ultimate role of this cytokine in disease, however, cannot be fully determined until the immunological contexts that regulate its function are further elucidated. In this review, we will discuss a wide variety of evidence of IL-10 in immunity and cancer in an effort to illuminate the remaining mysteries in the function of this cytokine that, when fully understood, may prove to be a powerful tool in the battle against cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：103 / 107

页数：5

共 96 条

[1]

IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response [J].

Adris, SK ;

Klein, S ;

Jasnis, MA ;

Chuluyan, E ;

Ledda, MF ;

Bravo, AI ;

Carbone, C ;

Chernajovsky, Y ;

Podhajcer, OL .

GENE THERAPY, 1999, 6 (10) :1705-1712

[2]

Mechanisms of interleukin-10-mediated immune suppression [J].

Akdis, CA ;

Blaser, K .

IMMUNOLOGY, 2001, 103 (02) :131-136

[3]

Anderson CF, 2002, J LEUKOCYTE BIOL, V72, P101

[4]

Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells [J].

Batten, Marcel ;

Kljavin, Noelyn M. ;

Li, Ji ;

Walter, Michael J. ;

de Sauvage, Frederic J. ;

Ghilardi, Nico .

JOURNAL OF IMMUNOLOGY, 2008, 180 (05) :2752-2756

[5]

Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation [J].

Berlato, C ;

Cassatella, MA ;

Kinjyo, I ;

Gatto, L ;

Yoshimura, A ;

Bazzoni, F .

JOURNAL OF IMMUNOLOGY, 2002, 168 (12) :6404-6411

[6]

MACROPHAGE DEACTIVATION BY INTERLEUKIN-10 [J].

BOGDAN, C ;

VODOVOTZ, Y ;

NATHAN, C .

JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (06) :1549-1555

[7]

Human interleukin-10 expression in T natural killer-cell lymphomas -: Association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas [J].

Boulland, ML ;

Meignin, V ;

Leroy-Viard, K ;

Copie-Bergman, C ;

Brière, J ;

Touitou, R ;

Kanavaros, P ;

Gaulard, P .

AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (04) :1229-1237

[8]

STATs in oncogenesis [J].

Bowman, T ;

Garcia, R ;

Turkson, J ;

Jove, R .

ONCOGENE, 2000, 19 (21) :2474-2488

[9]

Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma [J].

Boyano, MD ;

Garcia-Vázquez, MD ;

López-Michelena, T ;

Gardeazabal, J ;

Bilbao, J ;

Cañavate, ML ;

De Galdeano, AG ;

Izu, R ;

Díaz-Ramón, L ;

Raton, JA ;

Díaz-Pérez, JL .

BRITISH JOURNAL OF CANCER, 2000, 83 (07) :847-852

[10]

Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation [J].

Braun, David A. ;

Fribourg, Miguel ;

Sealfon, Stuart C. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (05) :2986-2993

← 1 2 3 4 5 6 7 8 9 10 →